Fresh Tracks Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Fresh Tracks Therapeutics, Inc. - overview
Established
2009
Location
Boulder, MX-COA-Coahuila, US
Primary Industry
Biotechnology
About
Founded in 2009 and based in Colorado, US, Brickell Biotech, Inc. develops topical therapeutics for hyperhidrosis, cutaneous T-cell lymphoma and psoriasis.
Current Investors
Oppenheimer, Palisade Capital Management, Amorepacific Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.brickellbio.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Fresh Tracks Therapeutics, Inc. - timeline of key events
Fresh Tracks Therapeutics, Inc. - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 30,018,000 | 17,519,000 | 7,718,000 | 15,217,000 | 20,950,000 | 14,531,000 | 13,819,000 | 1,622,000 | 7,917,000 | 1,822,000 | - | - | - |
| % Revenue Growth (YoY) | - | (41.6%) | (55.9%) | 97.2% | 37.7% | (30.6%) | (4.9%) | (88.3%) | 388.1% | (77.0%) | - | - | - |
| EBITDA (USD) | (5,524,000) | (21,449,000) | (29,139,000) | (14,963,000) | (8,245,000) | (8,060,000) | (12,593,000) | (19,495,000) | (22,865,000) | (20,966,000) | - | - | - |
| Operating Income (USD) | (7,822,000) | (23,433,000) | (31,352,000) | (16,626,000) | (9,404,000) | (9,177,000) | (13,386,000) | (19,646,000) | (24,468,000) | (20,976,000) | - | - | - |
| Operating Margin | (26.1%) | (133.8%) | (406.2%) | (109.3%) | (44.9%) | (63.2%) | (96.9%) | (1211.2%) | (309.1%) | (1151.3%) | - | - | - |
| % EBITDA Margin | (18.4%) | (122.4%) | (377.5%) | (98.3%) | (39.4%) | (55.5%) | (91.1%) | (1201.9%) | (288.8%) | (1150.7%) | - | - | - |
| NET Income (USD) | (7,283,000) | (22,899,000) | (31,238,000) | (16,492,000) | (9,238,000) | (8,973,000) | (12,960,000) | (16,254,000) | (23,877,000) | (20,913,000) | - | - | - |
| % Net Margin | (24.3%) | (130.7%) | (404.7%) | (108.4%) | (44.1%) | (61.8%) | (93.8%) | (1002.1%) | (301.6%) | (1147.8%) | - | - | - |
Fresh Tracks Therapeutics, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Placement/Follow on | Completed | Fresh Tracks Therapeutics, Inc. | - | ||||||||
| Private Placement/Follow on | Completed | Fresh Tracks Therapeutics, Inc. | - | ||||||||
| PIPE | Completed | Fresh Tracks Therapeutics, Inc. | - | ||||||||
| Merger | Completed | Vical Incorporated | - | ||||||||
| Unspecified Round | Completed | Fresh Tracks Therapeutics, Inc. | - |
Displaying 1 - 5 of 9
Fresh Tracks Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.